AXCELLA HEALTH INC. Research and Development Expense
AXCELLA HEALTH INC. reported Research and Development Expense of $1.22 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-08-03
- AXCELLA HEALTH INC. research and development expense for the quarter ending 2023-06-30 was $1.22M, a 92.74% decline year-over-year.
- AXCELLA HEALTH INC. research and development expense for the quarter ending 2023-03-31 was $1.43M, a 89.42% decline year-over-year.
- AXCELLA HEALTH INC. research and development expense for the quarter ending 2022-12-31 was $13.26M, a 6.34% increase year-over-year.
- AXCELLA HEALTH INC. research and development expense for the quarter ending 2022-09-30 was $13.32M, a 31.46% increase year-over-year.
- AXCELLA HEALTH INC. research and development expense for fiscal 2022 was $56.98M, a 32.11% increase from fiscal 2021.
- AXCELLA HEALTH INC. research and development expense for fiscal 2021 was $43.13M, a 16.46% increase from fiscal 2020.
- AXCELLA HEALTH INC. research and development expense for fiscal 2020 was $37.04M, a 11.09% decline from fiscal 2019.
- AXCELLA HEALTH INC. research and development expense for fiscal 2019 was $41.66M, a 63.45% increase from fiscal 2018.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-06-30 | $1.22M 10-Q · filed 2023-08-03 | $2.66M 10-Q · filed 2023-08-03 | $15.91M derived: sum of 3 quarters · filed 2023-08-03 | $29.23M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $1.43M 10-Q · filed 2023-05-04 | $14.69M derived: sum of 2 quarters · filed 2023-05-04 | $28.01M derived: sum of 3 quarters · filed 2023-05-04 | $44.87M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-12-31 | $13.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $26.57M derived: sum of 2 quarters · filed 2023-03-30 | $43.44M derived: sum of 3 quarters · filed 2023-08-03 | $56.98M 10-K · filed 2023-03-30 |
| 2022-09-30 | $13.32M 10-Q · filed 2022-11-01 | $30.18M derived: sum of 2 quarters · filed 2023-08-03 | $43.73M 10-Q · filed 2022-11-01 | $56.19M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-06-30 | $16.87M 10-Q · filed 2023-08-03 | $30.41M 10-Q · filed 2023-08-03 | $42.88M derived: sum of 3 quarters · filed 2023-08-03 | $53.01M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $13.54M 10-Q · filed 2023-05-04 | $26.01M derived: sum of 2 quarters · filed 2023-05-04 | $36.14M derived: sum of 3 quarters · filed 2023-05-04 | $46.44M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $12.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $22.60M derived: sum of 2 quarters · filed 2023-03-30 | $32.90M derived: sum of 3 quarters · filed 2023-03-30 | $43.13M 10-K · filed 2023-03-30 |
| 2021-09-30 | $10.13M 10-Q · filed 2022-11-01 | $20.43M derived: sum of 2 quarters · filed 2022-11-01 | $30.67M 10-Q · filed 2022-11-01 | $41.27M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $10.30M 10-Q · filed 2022-08-12 | $20.54M 10-Q · filed 2022-08-12 | $31.14M derived: sum of 3 quarters · filed 2022-08-12 | $38.68M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $10.24M 10-Q · filed 2022-05-05 | $20.84M derived: sum of 2 quarters · filed 2022-05-05 | $28.38M derived: sum of 3 quarters · filed 2022-05-05 | $36.94M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $10.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $18.14M derived: sum of 2 quarters · filed 2022-03-30 | $26.70M derived: sum of 3 quarters · filed 2022-03-30 | $37.04M 10-K · filed 2022-03-30 |
| 2020-09-30 | $7.54M 10-Q · filed 2021-11-10 | $16.11M derived: sum of 2 quarters · filed 2021-11-10 | $26.44M 10-Q · filed 2021-11-10 | $39.04M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $8.56M 10-Q · filed 2021-07-29 | $18.90M 10-Q · filed 2021-07-29 | $31.50M derived: sum of 3 quarters · filed 2021-07-29 | $43.65M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $10.34M 10-Q · filed 2021-05-06 | $22.93M derived: sum of 2 quarters · filed 2021-05-06 | $35.09M derived: sum of 3 quarters · filed 2021-05-06 | $44.43M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $12.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $24.75M derived: sum of 2 quarters · filed 2021-03-17 | $34.09M derived: sum of 3 quarters · filed 2021-03-17 | $41.66M 10-K · filed 2021-03-17 |
| 2019-09-30 | $12.16M 10-Q · filed 2020-11-12 | $21.50M derived: sum of 2 quarters · filed 2020-11-12 | $29.06M 10-Q · filed 2020-11-12 | $36.94M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $9.34M 10-Q · filed 2020-08-05 | $16.91M 10-Q · filed 2020-08-05 | $24.78M derived: sum of 3 quarters · filed 2020-08-05 | $30.93M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $7.56M 10-Q · filed 2020-05-11 | $15.44M derived: sum of 2 quarters · filed 2020-05-11 | $21.59M derived: sum of 3 quarters · filed 2020-05-11 | $27.59M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $7.88M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $14.02M derived: sum of 2 quarters · filed 2020-03-23 | $20.03M derived: sum of 3 quarters · filed 2020-03-23 | $25.49M 10-K · filed 2020-03-23 |
| 2018-09-30 | $6.15M 10-Q · filed 2019-11-12 | $12.15M derived: sum of 2 quarters · filed 2019-11-12 | $17.61M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $6.01M 10-Q · filed 2019-08-12 | $11.46M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $5.46M 10-Q · filed 2019-06-20 |